Orchard Therapeutics reports third quarter 2023 financial results and highlights recent business accomplishments
Orchard Therapeutics announced several business accomplishments along with its financial results for the quarter ended 30 September 2023.
Bobby Gaspar MD PhD, Chief Executive Officer of Orchard Therapeutics, said: “With strong execution across our key commercial, regulatory and clinical priorities, 2023 has been a transformational year for Orchard Therapeutics, culminating with the announcement of the planned acquisition by Kyowa Kirin.”
Selected HAE 2023 Expected Milestones
Orchard Therapeutics has outlined that for the remainder of 2023 it expects to advance the company’s other pre-clinical programs, which includes OTL-204 in the progranulin form of FTD and OTL-105 partnered with and funded by Pharming Group N.V. in hereditary angioedema (HAE).
(Source: Orchard)
